SPEXOTRAS

This brand name is authorized in Austria, Estonia, France, Croatia, Ireland, Italy, Lithuania, Romania

Active ingredients

The drug SPEXOTRAS contains one active pharmaceutical ingredient (API):

1 Trametinib UNII 33E86K87QN - TRAMETINIB

Trametinib is a reversible, highly selective, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and kinase activity. In melanoma and other cancers, this pathway is often activated by mutated forms of BRAF which activates MEK. Trametinib inhibits activation of MEK by BRAF and inhibits MEK kinase activity. Read about Trametinib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
SPEXOTRAS Powder for oral solution	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01EE01		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EE Mitogen-activated protein kinase (MEK) inhibitors
Discover more medicines within L01EE01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3064867
Country: FR	Base de données publique des médicaments	Identifier(s): 64421282
Country: IT	Agenzia del Farmaco	Identifier(s): 051049017
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1098663
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W70093001